276 results on '"Kircik, Leon H."'
Search Results
2. Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial
3. Generalized pustular psoriasis: A consensus statement from the National Psoriasis Foundation
4. Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial
5. Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug
6. 504 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis
7. INDIVIDUAL ARTICLE: Antibiotic Stewardship in Acne: 2023 Update
8. Benefit of Topical Combination Therapy for Acne: Analyzing Effect Size Using Number Needed to Treat
9. The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score
10. The Right Formula for Acne: Importance of Vehicle Formulation in Tazarotene 0.045% Lotion Design, Application, Tolerability, and Efficacy.
11. Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study
12. Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis
13. Triple‐combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel for moderate‐to‐severe acne in children and adolescents: Randomized phase 2 study
14. Improvements in acne and skin oiliness with tazarotene 0.045% lotion in patients with oily skin
15. Gram-Negative Folliculitis
16. Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial
17. 640 - Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis.
18. Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis
19. 33463 Pooled efficacy and safety results from the DERMIS-1 and DERMIS-2 phase 3 trials of once-daily roflumilast cream 0.3% by baseline body surface area
20. 32970 Efficacy and safety of a fixed-dose clindamycin 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15% gel for moderate-to-severe acne: Randomized phase 2 and phase 3 studies of the first triple-combination drug
21. Efficacy and tolerability of three topical acne treatments by body mass index: post hoc analysis including overweight and obese patients
22. Dermal sensitization, safety, and tolerability of triple-combination clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15% gel from three clinical trials.
23. Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug
24. Dermal sensitization, safety, tolerability, and patient preference of tazarotene 0.045% lotion from five clinical trials
25. Androgens and acne: perspectives on clascoterone, the first topical androgen receptor antagonist
26. Gram-Negative Folliculitis
27. Doxycycline and minocycline for the management of acne: a review of efficacy and safety with emphasis on clinical implications
28. How and when to use biologics in Psoriasis
29. Scalp psoriasis
30. Harnessing the anti-inflammatory effects of topical dapsone for management of acne
31. Investigator- and patient-rated local tolerability in phase 3 trials of topical roflumilast in patients with psoriasis, seborrheic dermatitis, and atopic dermatitis.
32. Tretinoin microsphere gel pump 0.04% versus tazarotene cream 0.05% in the treatment of mild-to-moderate facial acne vulgaris
33. Comparative efficacy and safety results of two topical combination acne regimens
34. Anti-TNF agents for the treatment of psoriasis
35. Critical reviews of clinical data: focus on T cell agents for the treatment of psoriasis
36. Dermal sensitization, safety, tolerability, and patient preference of tazarotene 0.045% lotion from five clinical trials.
37. Treatment of moderate to severe plaque psoriasis with concomitant efalizumab and narrow-band ultraviolet B phototherapy
38. Trolamine/sodium alginate topical emulsion versus bacitracin/polymyxin b ointment in second-intention healing following mohs micrographic surgery
39. The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study
40. Histologic improvement in photodamage after 12 months of treatment with tretinoin emollient cream (0.02%)
41. Trial of Roflumilast Cream for Chronic Plaque Psoriasis
42. A Randomized, Observer‑Blind, Split‑Face Study to Assess Compatibility of Facial Foundation Makeup with Tretinoin 0.05% Lotion and Skin Texture After Application
43. The clinical efficacy and safety of tretinoin for the treatment of aging skin
44. Novel tretinoin 0.05% lotion for the once-daily treatment of moderate-to-severe acne vulgaris in an adult and adolescent female population
45. Vulvar Squamous Cell Carcinoma Metastatic to the Skin
46. A Discussion of the Pathophysiology of Acne and Available Treatment Strategies.
47. A Split-face, Controlled Study to Assess the Compatibility of Tretinoin 0.05% Acne Lotion with Facial Foundation Makeup.
48. WITHDRAWN: Efficacy and safety of topical oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 2 phase 3, 29-day, randomized, controlled REVEAL trials
49. Importance of Vehicles in Topical Treatment of Fungal Infections
50. Nonsteroidal Treatment of Atopic Dermatitis in Pediatric Patients with a Ceramide-Dominant Topical Emulsion Formulated with an Optimized Ratio of Physiological Lipids
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.